Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 77 Melanoma 51 Squamous Cell Carcinoma of Head and Neck 40 Neoplasm Metastasis 29 Neoplasms 26 Breast Neoplasms 25 Colorectal Neoplasms 23 Carcinoma, Renal Cell 23 Head and Neck Neoplasms 21 Triple Negative Breast Neoplasms 20 Carcinoma, Transitional Cell 20 Stomach Neoplasms 19 Ovarian Neoplasms 17 Lung Neoplasms 15 Uterine Cervical Neoplasms 12 Esophageal Neoplasms 12 Carcinoma, Hepatocellular 12 Urinary Bladder Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 11 Pancreatic Neoplasms 10 Small Cell Lung Carcinoma 9 Multiple Myeloma 9 Recurrence 8 Endometrial Neoplasms 8 Carcinoma, Merkel Cell 8 Lymphoma, Non-Hodgkin 7 Lymphoma 7 Skin Neoplasms 6 Mesothelioma 6 Hodgkin Disease 6

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Cancer × pembrolizumab × Clear all

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡